Elamipretide

Elamipretide has been studied in 431 papers since 1977: 21 trials and 37 observational studies in people, 208 in animals, 61 in cells, 90 reviews; 43 in the past year. It is an approved medicine. The newest story, Oct 3, 2026: “Elamipretide improves oocyte quality and restores fertility in aged mice”.

InterventionApproved 2025

431 papers study it1 more mentions it351 findingsUpdated

PubChemChEBIMeSH

More peptides

1 new paper in 30 daysSee all 138 papers on elamipretide

At a glance

Elamipretide improves muscle function in aged mice, and independent labs reproduce reduced inflammation in mice; a human trial in primary mitochondrial myopathy shows no clear fatigue or walking benefit. Two registered trials concern aging; seven trials across uses ended over a year ago without posted results or citing papers. Most trials are company-sponsored; 2 of 6 human papers declare developer ties.

351 findings in 101 papers from 2006 to 2026, 6 of them since May 2026

The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 47 independent labs in 10 countries; 24 trials, 2 about aging, 7 with no results posted.

“The LS mean (SE) of change from baseline to week 24 on the PMMSA TFS was −1.13 (±0.22) for participants receiving elamipretide and −1.05 (±0.22) for participants receiving placebo, a −0.07 difference between the 2 groups (95% CI −0.69 to 0.54; p = 0.81).”
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical TrialNeurology2023doi:10.1212/wnl.0000000000207402

6 of its findings point the other way.

Cells and mice: replicated by independent labs. Worms or flies and humans: a single group.
  • 47 independent labs in 10 countries
  • 6 findings against
  • 24 trials, 2 about aging, 7 with no results posted
  • Funders: National Institute on Aging and others
  • 45 of 332 findings with company ties
  • 24 of 24 trials sponsored by its developers
  • Human trial6
  • Humans3
  • Animals84
  • Model organisms1
  • Cells13

6 studies gave elamipretide to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on 6-Minute Walk Test distance−3.2-meter difference (95% CI −18.7 to 12.3)

no change: Has no effect on fatigue−0.07 difference (95% CI −0.69 to 0.54)

Randomized trial24 weeks218 peoplefemale (64.2% n = 140/218)mean age was 44.9 yearsAdults with primary mitochondrial myopathies (PMM)Neurology, Jun 2, 2023

up: Improves best-corrected visual acuity+4.6 ± 5.1 letters

up: Improves low-luminance best-corrected visual acuity+5.4 ± 7.9 letters

up: Increases geographic atrophy area

Trial24 weeks19 peoplemost participant were women (11/19)mean age 76 yearsPatients with dry age-related macular degeneration and noncentral geographic atrophyOphthalmology science, Nov 27, 2021

no change: Has no effect on mitochondrial coupling

no change: Has no effect on fatigue resistance

Randomized trial2 hours39 peopleBoth60 to 85 years of ageAdults in overall good general health presenting with low mitochondrial functionPloS one, Jul 15, 2021

down: Decreases left ventricular end-diastolic volume-18 mL vs placebo, P=0.009; end-systolic volume -14 mL, P=0.005

no change: Has no effect on serious adverse events

no change: Has no effect on blood pressurestable in all cohorts

Randomized trial4-hour infusion8 peopleHighest dose cohort vs placebo, at end infusionCirculation. Heart failure, Dec 1, 2017

down: Decreases fractional hypoxia

up: Increases renal blood flow

up: Improves estimated glomerular filtration rate40.7±13.4 to 46.5±15 vs 34.4±9.5 to 37±10.5 ml/min/1.73m2

Randomized trial3 hours14 peoplePatients with severe atherosclerotic renal artery stenosisCirculation. Cardiovascular interventions, Sep 1, 2017

What did studies of elamipretide find?

256

Studies of elamipretide measured 256 outcomes; the most studied are oxidative stress and ROS signaling (12 studies), inflammation (11) and apoptosis (7).

Oxidative stress and ROS signaling

downin mice4downin reviews4downin animals1downin cells1+2

12 studies
  1. Elamipretide decreases oxidative stress and ROS signaling.

    “This mitochondria-targeting tetrapeptide selectively binds cardiolipin (CL), a lipid found in the inner mitochondrial membrane, thus stabilizing mitochondrial cristae structure, reducing oxidative stress, and enhancing adenosine triphosphate (ATP) production.”

    Review

    Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

    International journal of molecular sciences

  2. Elamipretide decreases oxidative stress and ROS signaling in cells (cigarette smoke extract-damaged oral epithelial cells).

    “SS-31 plays a protective role against cigarette smoke extract (CSE) by reducing oxidative stress, attenuating inflammatory response, and restoring mitochondrial function.”

    Cellscigarette smoke extract-damaged oral epithelial cellsoral epithelial cells

    SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette smoke-damaged oral epithelial cells via PINK1-mediated mitophagy

    Chemico-biological interactions

  3. Elamipretide decreases oxidative stress and ROS signaling in mice after vitrification and resuscitation.

    “significantly reduced apoptosis (p < 0.05) and oxidative stress levels”

    Animalsafter vitrification and resuscitationovary100 μmol/Lfemales

    Effect of Elamipretide on the Vitrification of Mouse Ovarian Tissue by Freezing

    Biopreservation and biobanking

  4. Elamipretide decreases oxidative stress and ROS signaling.

    “Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes”

    Review

    Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction

    Mitochondrion

  5. Elamipretide decreases oxidative stress and ROS signaling.

    “In addition, elamipretide has been shown to attenuate neural oxidative stress”

    Review

    Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration

    Frontiers in integrative neuroscience

  6. Elamipretide inhibits oxidative stress and ROS signaling.

    “Mitochondria-targeted chemicals, such as the Szeto-Schiller-31 peptide, have advanced therapeutic potential through the inhibition of oxidative stress”

    Review

    Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease

    Pharmacological research

  7. Elamipretide decreases oxidative stress and ROS signaling during hepatic ischemia-reperfusion injury.

    “oxidative stress and inflammation were significantly suppressed after SS-31 administration”

    Animalsduring hepatic ischemia-reperfusion injuryliver

    SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage Polarization

    Oxidative medicine and cellular longevity

  8. Elamipretide decreases oxidative stress and ROS signaling in mice.

    “SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice”

    Animalsheart8 weeks

    Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

    eLife

  9. Elamipretide protects against oxidative stress and ROS signaling in LPS-treated mice.

    “elamipretide not only provided protective effects against mitochondrial dysfunction and oxidative stress”

    Animalsin LPS-treated micehippocampus

    Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice

    Journal of neuroinflammation

  10. Elamipretide decreases oxidative stress and ROS signaling in mouse cells (LPS-stimulated BV-2 cells).

    “SS-31 defended the BV-2 cells against LPS-stimulated inflammation and oxidative stress via suppressing Fis1.”

    CellsLPS-stimulated BV-2 cells

    SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia

    Biochemical and biophysical research communications

All 12

More on Oxidative stress and ROS signaling

Inflammation

downin mice4downin human cells2downin animals1downin cells1+3

11 studies
  1. Elamipretide decreases inflammation in mice (high-fat, high-fructose diet-induced MASLD; measured as NF-?B and NLRP3 activation).

    “Both compounds attenuated inflammation by suppressing NF-?B and NLRP3 activation.”

    Animalshigh-fat, high-fructose diet-induced MASLD; measured as NF-?B and NLRP3 activationliver3 mg/kg/day16 weeksfemales

    Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress

    Physiological research

  2. Elamipretide decreases inflammation in rats (neuroinflammation in LPS-treated aged rats).

    “SS-31 pretreatment attenuated eGC degradation, reduced neuroinflammation, and restored PSD-95 levels”

    Animalsneuroinflammation in LPS-treated aged ratshippocampusmales

    Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive Impairment in Aged Rats: Protective Role of SS-31

    Molecular neurobiology

  3. Elamipretide decreases inflammation in mice.

    “upregulation of genes involved in fatty acid metabolism, mitochondrial translation, and oxidative phosphorylation, and downregulation of inflammation”

    Animals8-week

    The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age

    Aging cell

  4. Elamipretide decreases inflammation in cells (cigarette smoke extract-damaged oral epithelial cells).

    “SS-31 plays a protective role against cigarette smoke extract (CSE) by reducing oxidative stress, attenuating inflammatory response, and restoring mitochondrial function.”

    Cellscigarette smoke extract-damaged oral epithelial cellsoral epithelial cells

    SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette smoke-damaged oral epithelial cells via PINK1-mediated mitophagy

    Chemico-biological interactions

  5. Elamipretide decreases inflammation in human cells (LPS-stimulated HepG2 cells).

    “SS-31 safeguards HepG2 cells against inflammatory responses triggered by LPS”

    CellsLPS-stimulated HepG2 cells

    SS-31 inhibits the inflammatory response by increasing ATG5 and promoting autophagy in lipopolysaccharide-stimulated HepG2 cells

    Biochemical and biophysical research communications

  6. Elamipretide decreases inflammation.

    “Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes”

    Review

    Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction

    Mitochondrion

  7. Elamipretide decreases inflammation during hepatic ischemia-reperfusion injury.

    “The proinflammation cytokines are then significantly reduced, which suppress inflammation response in the liver.”

    Animalsduring hepatic ischemia-reperfusion injuryliver

    SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage Polarization

    Oxidative medicine and cellular longevity

  8. Elamipretide decreases inflammation in mouse cells (LPS-stimulated BV-2 cells).

    “SS-31 defended the BV-2 cells against LPS-stimulated inflammation and oxidative stress via suppressing Fis1.”

    CellsLPS-stimulated BV-2 cells

    SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia

    Biochemical and biophysical research communications

  9. Elamipretide decreases inflammation in leukocytes of type 2 diabetes patients; NF-κB p65 and TNF-α as markers.

    “NFκB-p65 and TNFα, which were enhanced in diabetic patients, were also reduced by SS-31 treatment.”

    Cellsin leukocytes of type 2 diabetes patients; NF-κB p65 and TNF-α as markers

    The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes

    Scientific reports

  10. Elamipretide decreases inflammation in mice (ischemia-reperfusion model).

    “The IR-induced increase of levels of inflammatory factors, such as Tnf-α and Il-1β, was prevented by SS-31 treatment.”

    Animalsischemia-reperfusion modelhind limb

    Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury

    Journal of physiology and biochemistry

All 11

More on Inflammation

Apoptosis

downin mice3downin human cells2downin mouse cells1downin rats1

7 studies
  1. Elamipretide decreases apoptosis in human cells (oxidative damage).

    “Treatment alleviated oxidative damage-induced apoptosis”

    Cellsoxidative damagegranulosa cells

    Dual action of SS31 via NRF2/HO-1: countering oxidative stress and metabolic dysfunction in ovarian aging

    Journal of ovarian research

  2. Elamipretide decreases apoptosis in human cells (cisplatin-treated HK-2 cells).

    “SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells”

    Cellscisplatin-treated HK-2 cells100 μM

    Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  3. Elamipretide decreases apoptosis in mice after traumatic brain injury.

    “thus attenuating neurological deficits, brain water content, DNA damage, and neural apoptosis”

    Animalsafter traumatic brain injurybrain5 mg/kg

    SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury

    Oxidative medicine and cellular longevity

  4. Elamipretide decreases apoptosis in mice (streptozotocin-diabetic mice).

    “SS-31 attenuated renal cell apoptosis and expression of Bax and reversed the expression of Bcl-2 in diabetic mice kidneys.”

    Animalsstreptozotocin-diabetic micekidney8 wk

    Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy

    American journal of physiology. Renal physiology

  5. Elamipretide decreases apoptosis in mice (isoflurane-treated aging mice).

    “inhibited the apoptotic pathway by decreasing the Bax/Bcl-2 ratio, reducing the release of cytochrome C, and blocking the cleavage of caspase 3.”

    Animalsisoflurane-treated aging micehippocampus

    A Mitochondrion-Targeted Antioxidant Ameliorates Isoflurane-Induced Cognitive Deficits in Aging Mice

    PloS one

  6. Elamipretide decreases apoptosis in rats after renal ischemia.

    “Rapid recovery of ATP also inhibited apoptosis, protected tubular barrier function, and mitigated renal dysfunction.”

    Animalsafter renal ischemiakidney

    The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin

    Journal of the American Society of Nephrology : JASN

  7. Elamipretide decreases apoptosis in mouse cells.

    “Herein is demonstrated that SS-31 readily penetrates intact mouse islets, preserves mitochondrial polarization, reduces islet cell apoptosis, and increases islet cell yield.”

    Cellspancreatic islet

    Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function

    Journal of the American Society of Nephrology : JASN

More on Apoptosis

Reactive oxygen species

downin human cells2downin mice2downin animals1downin mouse cells1+1−40%

7 studies
  1. Elamipretide decreases reactive oxygen species in mouse cells (oocytes from aged mice).

    “SS-31 reduced oocyte aneuploidy, ROS accumulation and DNA damage.”

    Cellsoocytes from aged miceoocytefemales

    SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism

    Journal of ovarian research

  2. Elamipretide decreases reactive oxygen species in human cells (genotype-dependent, patient-derived fibroblasts).

    “In patient fibroblasts, elamipretide produced a possible genotype-dependent increase in mitochondrial bioenergetics and a reduction in ROS.”

    Cellsgenotype-dependent, patient-derived fibroblasts

    Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts

    Journal of inherited metabolic disease

  3. Elamipretide decreases reactive oxygen species in aged BM-MSCs (-40%).

    “reducing ROS levels by 40% in aged BM-MSCs”

    Cellsin aged BM-MSCsbone marrow-derived mesenchymal stem cells

    SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function

    Organogenesis

  4. Elamipretide decreases reactive oxygen species in rats with severe burns plus delayed resuscitation.

    “neutralizing ROS, inhibiting the release of mtDNA”

    Animalsin rats with severe burns plus delayed resuscitation

    SS-31 ameliorates hepatic injury in rats subjected to severe burns plus delayed resuscitation via inhibiting the mtDNA/STING pathway in Kupffer cells

    Biochemical and biophysical research communications

  5. Elamipretide decreases reactive oxygen species in sleep-deprived aged mice.

    “reactive oxygen species (ROS) and inflammatory cytokines levels were decreased in the hippocampus”

    Animalsin sleep-deprived aged micehippocampus3 mg/kgfour daysfemales

    Adverse Neurological Effects of Short-Term Sleep Deprivation in Aging Mice Are Prevented by SS31 Peptide

    Clocks & sleep

  6. Elamipretide decreases reactive oxygen species in mice after traumatic brain injury.

    “SS-31 can directly decrease the ROS content”

    Animalsafter traumatic brain injurybrain5 mg/kg

    SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury

    Oxidative medicine and cellular longevity

  7. Elamipretide decreases reactive oxygen species (cecal ligation and puncture sepsis).

    “inducible nitric oxide synthase, reactive oxygen species, and TUNEL-positive cells”

    Animalscecal ligation and puncture sepsis5 mg/kg

    Protective Effects of Antioxidant Peptide SS-31 Against Multiple Organ Dysfunctions During Endotoxemia

    Inflammation

More on Reactive oxygen species

Mitochondrial function

upin mice2upin cells1no changein dogs1upin reviews1

5 studies
  1. Elamipretide improves mitochondrial function in cells (cigarette smoke extract-damaged oral epithelial cells).

    “SS-31 plays a protective role against cigarette smoke extract (CSE) by reducing oxidative stress, attenuating inflammatory response, and restoring mitochondrial function.”

    Cellscigarette smoke extract-damaged oral epithelial cellsoral epithelial cells

    SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette smoke-damaged oral epithelial cells via PINK1-mediated mitophagy

    Chemico-biological interactions

  2. Elamipretide improves mitochondrial function in mice (repeated IS infusion).

    “These IS-induced damages in TNC were reversed by SS-31.”

    Animalsrepeated IS infusiontrigeminal nucleus caudalis

    SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop

    The journal of headache and pain

  3. Elamipretide improves mitochondrial function.

    “restoration of normal mitochondrial function as compared to traditional antioxidants, such as vitamin E.”

    Review

    Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease

    Pharmacological research

  4. Elamipretide showed no clear effect on mitochondrial function in vitro exposure of myofibrillar mitochondria from normal dogs.

    “Exposure of skeletal muscle myofibrillar mitochondria from normal dogs to ELAM had no effect on mitochondrial function parameters.”

    Animalsin vitro exposure of myofibrillar mitochondria from normal dogsskeletal muscle mitochondria1 h

    Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure

    ESC heart failure

  5. Elamipretide improves mitochondrial function in mice after traumatic brain injury.

    “SS-31 improves the mitochondrial function and provides neuroprotection in mice after TBI”

    Animalsafter traumatic brain injury5 mg/kg

    SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury

    Oxidative medicine and cellular longevity

Diastolic function

upin mice3upin animals1

4 studies
  1. Elamipretide improves diastolic function in mice (both sexes; larger effect in males) (larger effect in males than in females; no numeric value given).

    “It also improved diastolic function in both males and females, but to a greater extent in males.”

    Animalsboth sexes; larger effect in malesheart3 mg/kg subcutaneously, 5 days per week10 months

    Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice

    Aging pathobiology and therapeutics

  2. Elamipretide improves diastolic function (cardiac aging).

    “leads to substantial reversal of diastolic dysfunction”

    Animalscardiac agingheart

    Reduction of elevated proton leak rejuvenates mitochondria in the aged cardiomyocyte

    eLife

  3. Elamipretide improves diastolic function in mice (old mice).

    “SS-31 partially reversed an age-related decline in diastolic function”

    Animalsold miceheart

    SS-31 and NMN: Two paths to improve metabolism and function in aged hearts

    Aging cell

  4. Elamipretide improves diastolic function in mice.

    “8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit”

    Animalsheart8 weeks

    Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

    eLife

Mitochondrial reactive oxygen species production

downin cells1downin human cells1downin reviews1

3 studies
  1. Elamipretide decreases mitochondrial reactive oxygen species production in cells.

    “Moreover, SS-31 mitigated mitochondrial production of reactive oxygen species.”

    Cells

    Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence

    Journal of radiation research

  2. Elamipretide decreases mitochondrial reactive oxygen species production.

    “it decreases mitochondrial reactive oxygen species production and prevents mitochondrial depolarization, mitochondrial permeability transition pore formation, and Ca2+-induced mitochondrial swelling”

    Review

    SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease

    Oxidative medicine and cellular longevity

  3. Elamipretide decreases mitochondrial reactive oxygen species production in leukocytes of type 2 diabetes patients.

    “We observed increased mitochondrial ROS production that was restored by SS-31 treatment.”

    Cellsin leukocytes of type 2 diabetes patients

    The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes

    Scientific reports

More on Mitochondrial reactive oxygen species production

Mitophagy

upin mice2upin mouse cells1

3 studies
  1. Elamipretide increases mitophagy in mouse cells (oocytes from aged mice).

    “SS-31 remarkably restored the normal spindle/chromosome structure, fertilization ability, mitochondrial distribution, ΔΨm and mitophagy in aged oocytes.”

    Cellsoocytes from aged miceoocytefemales

    SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism

    Journal of ovarian research

  2. Elamipretide activates mitophagy in surgically aged mice.

    “SS-31 interacted with PHB2 to activate mitophagy”

    Animalsin surgically aged mice

    SS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in aged mice

    Inflammation research : official journal of the European Histamine Research Society ... [et al.]

  3. Elamipretide improves mitophagy in mice.

    “with SS31 is associated with some improvements in oxidative damage and mitophagy in muscles of old mice.”

    Animalsskeletal muscle

    Mitochondrial ROS regulate oxidative damage and mitophagy but not age-related muscle fiber atrophy

    Scientific reports

More on Mitophagy

Ferroptosis

downin rats2downin mice1

3 studies
  1. Elamipretide decreases ferroptosis in microglia after cardiac arrest.

    “SS-31 attenuated ferroptosis and promoted an anti-inflammatory shift”

    Animalsin microglia after cardiac arrestmicroglia

    SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  2. Elamipretide inhibits ferroptosis in diabetic cardiomyopathy.

    “improving DCM by alleviating mitochondria‐dependent ferroptosis”

    Animalsin diabetic cardiomyopathy

    New insight for SS‑31 in treating diabetic cardiomyopathy: Activation of mitoGPX4 and alleviation of mitochondria‑dependent ferroptosis

    International journal of molecular medicine

  3. Elamipretide inhibits ferroptosis in rats (pilocarpine-induced epilepsy model).

    “SS-31 and SB203580 treatment blocked the initiation and progression of ferroptosis in the hippocampus of epileptic rats”

    Animalspilocarpine-induced epilepsy modelhippocampus

    Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats

    Brain research

More on Ferroptosis

Inflammatory cytokines

downin mice2downin rats1

3 studies
  1. Elamipretide decreases inflammatory cytokines in chronic sleep deprivation mice.

    “the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha”

    Animalsin chronic sleep deprivation mice5 mg/kg21 days

    Mitochondrial antioxidant elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice

    Brain and behavior

  2. Elamipretide decreases inflammatory cytokines in rats after LPS exposure.

    “rats with SS-31 treatment showed lower levels of inflammatory cytokines”

    Animalsafter LPS exposurehippocampus

    Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related Regions Following Prolonged Neuroinflammation Induced by Lipopolysaccharide in Aged Rats

    Frontiers in aging neuroscience

  3. Elamipretide decreases inflammatory cytokines in sleep-deprived aged mice.

    “reactive oxygen species (ROS) and inflammatory cytokines levels were decreased in the hippocampus”

    Animalsin sleep-deprived aged micehippocampus3 mg/kgfour daysfemales

    Adverse Neurological Effects of Short-Term Sleep Deprivation in Aging Mice Are Prevented by SS31 Peptide

    Clocks & sleep

More on Inflammatory cytokines

Oxidative phosphorylation

upin humans1upin reviews1

2 studies
  1. Elamipretide increases oxidative phosphorylation in humans.

    “The primary outcome of this study was an elevated ATPmax in the ELAM group versus the placebo group immediately after a 2-hour ELAM infusion (P = 0.055 for delta ATPmax and P = 0.045 for %change, ).”

    Human trialskeletal muscle2 hours

    In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

    PloS one

  2. Elamipretide increases oxidative phosphorylation.

    “elamipretide enhanced mitochondrial respiration”

    Review

    Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration

    Frontiers in integrative neuroscience

More on Oxidative phosphorylation

Best-corrected visual acuity

upin humans1

1 study
  1. Elamipretide improves best-corrected visual acuity in humans among participants completing the study, uncontrolled (+4.6 (5.1) letters).

    “mean ± standard deviation (SD) change in BCVA from baseline to week 24 was +4.6 (5.1) letters (P = 0.0032)”

    Human trialamong participants completing the study, uncontrolled40-mg daily24 weeksn = 15

    Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study

    Ophthalmology science

  2. Elamipretide improves best-corrected visual acuity in humans (+4.6 ± 5.1 letters).

    “Among the 15 participants who completed the active study period, the mean change in BCVA from baseline increased progressively over time, with a mean ± SD increase of 4.6 ± 5.1 letters (P = 0.0032; P < 0.0125, Holm method threshold for statistical significance) at week 24 ( A, B).”

    Human trial24 weeksn = 15

    Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study

    Ophthalmology science

ATPmax

no changein humans1upin humans1

1 study
  1. Elamipretide showed no clear effect on ATPmax in humans (measured on day 7 after treatment).

    “No difference was found on day 7 after treatment, which is consistent with the half-life of ELAM in human blood.”

    Human trialmeasured on day 7 after treatmentfirst dorsal interosseous musclesingle dose

    In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

    PloS one

  2. Elamipretide increases ATPmax in humans (versus placebo, measured immediately after a 2-hour infusion) (ΔATPmax P = 0.055; %ΔATPmax P = 0.045).

    “A single ELAM dose elevated mitochondrial energetic capacity in vivo relative to placebo (ΔATPmax; P = 0.055, %ΔATPmax; P = 0.045) immediately after a 2-hour infusion.”

    Human trialversus placebo, measured immediately after a 2-hour infusionfirst dorsal interosseous musclesingle dose2 hours

    In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

    PloS one

More on ATPmax

Estimated glomerular filtration rate

upin humans1

1 study
  1. Elamipretide improves estimated glomerular filtration rate in humans (over 3 months after PTRA, elamipretide compared with placebo) (P=0.003 within elamipretide group; P=0.11 between groups).

    “estimated glomerular filtration rate increased (P=0.003) more in the elamipretide group than in the placebo group (P=0.11).”

    Human trialover 3 months after PTRA, elamipretide compared with placebokidney0.05 mg/kg per hour3 months

    Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

    Circulation. Cardiovascular interventions

  2. Elamipretide improves estimated glomerular filtration rate in humans (40.7±13.4 to 46.5±15 vs 34.4±9.5 to 37±10.5 ml/min/1.73m2).

    “As a result, eGFR increased (from 40.7±13.4 to 46.5±15 ml/min/1.73m2, P=0.002) in the Elamipretide group and from 34.4±9.5 to 37±10.5 ml/min/1.73m2, P=0.24) in the placebo group.”

    Human trial3 hoursn = 14

    Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

    Circulation. Cardiovascular interventions

Renal blood flow

upin humans1

1 study
  1. Elamipretide increases renal blood flow in humans (elamipretide-treated group only, 3 months after PTRA) (202±29 to 262±115 mL/min).

    “Stenotic kidney RBF rose (202±29-262±115 mL/min; P=0.04) 3 months after PTRA in the elamipretide-treated group only.”

    Human trialelamipretide-treated group only, 3 months after PTRAkidney0.05 mg/kg per hour3 monthsn = 6

    Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

    Circulation. Cardiovascular interventions

  2. Elamipretide increases renal blood flow in humans.

    “The total SK volume did not change in either placebo or Elamipretide groups while total RBF and cortical blood flow increased only in the Elamipretide group,.”

    Human trial3 hoursn = 14

    Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

    Circulation. Cardiovascular interventions

All 256

What is elamipretide linked with?

7

Studies link elamipretide with 7 measures, among them non-mitochondrial proteins, mitochondria-associated proteins and Calcium distribution at the membrane interface.

Non-mitochondrial proteins

mixedin mice1

1 study
  1. Elamipretide is associated with non-mitochondrial proteins in mice.

    “Administration of SS-31 affected many non-mitochondrial proteins.”

    Animalscortical microvessels2 weeksmales

    Targeting mitochondria in the aged cerebral vasculature with SS-31, a proteomic study of brain microvessels

    GeroScience

More on Non-mitochondrial proteins

Mitochondria-associated proteins

mixedin mice1

1 study
  1. Elamipretide is associated with mitochondria-associated proteins in mice (107 significantly differentially expressed proteins).

    “Of this 12%, 107 were significantly differentially expressed and were associated with oxidative phosphorylation, metabolism, the antioxidant defense system, or mitochondrial dynamics.”

    Animalscortical microvessels2 weeksmales

    Targeting mitochondria in the aged cerebral vasculature with SS-31, a proteomic study of brain microvessels

    GeroScience

More on Mitochondria-associated proteins

Calcium distribution at the membrane interface

mixedin silico1

1 study
  1. Elamipretide is associated with calcium distribution at the membrane interface in silico (calcium stress).

    “SS-31 alters divalent cation (calcium) distribution within the interfacial region”

    In silicocalcium stress

    The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action

    The Journal of biological chemistry

Membrane surface electrostatics

mixedin silico1

1 study
  1. Elamipretide is associated with membrane surface electrostatics in silico (model and mitochondrial membranes).

    “Most notably, SS-31 modulated the surface electrostatics of both model and mitochondrial membranes.”

    In silicomodel and mitochondrial membranes

    The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action

    The Journal of biological chemistry

Membrane surface charge

upin silico1

1 study
  1. Elamipretide is associated with membrane surface charge in silico (model and mitochondrial membranes).

    “this polybasic peptide partitions into the membrane interfacial region with an affinity and a lipid binding density that are directly related to surface charge”

    In silicomodel and mitochondrial membranes

    The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action

    The Journal of biological chemistry

Cardiolipin

upin rat cells1

1 study
  1. Elamipretide is associated with cardiolipin in rat cells.

    “SS-31 binds with high affinity to cardiolipin”

    Cellspolarity-sensitive fluorescent analog

    The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin

    Journal of the American Society of Nephrology : JASN

Normoglycemia after islet transplantation

upin mice1

1 study
  1. Elamipretide is associated with normoglycemia after islet transplantation in mice (marginal islet mass transplantation under the renal capsule in syngeneic diabetic mice).

    “SS-31 treatment was associated with prompt and sustained normoglycemia, whereas the untreated islet graft recipients remained diabetic.”

    Animalsmarginal islet mass transplantation under the renal capsule in syngeneic diabetic mice

    Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function

    Journal of the American Society of Nephrology : JASN

Has elamipretide been tested in people?

2 of 24 about aging

Yes: 21 trials and 37 observational studies in people have been published, and 23 trials are registered.

Approved

Repurposing

All 12

Every condition in trials

  • Chronic progressive external ophthalmoplegia

    Phase 3Completed1 trial

  • Optic atrophy hereditary leber

    Phase 2Results posted1 trial

  • Skeletal muscle mitochondrial dysfunction in the elderly

    Phase 2Results posted1 trial

  • Fuchs' endothelial dystrophy

    Phase 1/2Results posted1 trial

  • Renal artery obstruction

    Phase 1/2Terminated1 trial

Stopped

  • NCT03323749TerminatedMuscular disease

    Part1,double blind portion of the trial did not meet the primary end points

  • NCT02976038TerminatedPrimary mitochondrial disease

    Registration trial did not meet the primary end points

Who is developing elamipretide?

1 company: Stealth BioTherapeutics.

Companies
  • Stealth BioTherapeuticsPhase 3age-related macular degeneration, mitochondrial myopathies

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Elamipretide improves endurance in aged female mice; independent labs reproduce reduced apoptosis in mice and oxidative stress in mouse cells. A preprint reports unchanged epigenetic and transcriptomic age in most treated mouse groups; one group reports human results. Two trials concern aging; seven across uses ended over a year ago without posted results, and developer Stealth BioTherapeutics sponsors 22 of 23 trials.

  2. Summary rewritten as its findings changed.

    As it read before

    One study reports that elamipretide improves mouse oocyte maturation and increases litter size in female mice, increases maturation and fertilization in human oocytes, and improves developmental competence in pig oocytes under oxidative damage.

  3. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 4Feb 2026: 1Mar 2026: 2Apr 2026: 1May 2026: 2Jun 2026: 1Jul 2026: 2Aug 2026: 2Sep 2026: 1Oct 2026: 5Nov 2026: 022 papers in 12 months
Science Advances

Layered gel improved spinal disc structure and function in rats

An experiment in rats with severe spinal disc degeneration found that a cell-carrying gel promoted new tissue formation and outperformed cells or a support scaffold…An experiment in rats with severe spinal disc degeneration found that a cell-carrying gel promoted new tissue formation and outperformed cells or a support scaffold alone.

Rat studyInterventions
Brain, Behavior, and Immunity

Cell energy problems linked to lasting memory deficits in aged rats

A compound targeting cells’ energy-producing structures restored memory when given four weeks after surgery in aged rats that also received morphine.A compound targeting cells’ energy-producing structures restored memory when given four weeks after surgery in aged rats that also received morphine.

Rat studyMechanisms

See all 138 papers on elamipretide